Invention Grant
- Patent Title: Substituted pyridines as DNMT1 inhibitors
-
Application No.: US17966504Application Date: 2022-10-14
-
Publication No.: US11771711B2Publication Date: 2023-10-03
- Inventor: Andrew B. Benowitz , David T. Fosbenner , Bryan Wayne King , Stuart Paul Romeril
- Applicant: GlaxoSmithKline Intellectual Property Development Limited
- Applicant Address: GB Brentford
- Assignee: GlaxoSmith Kline Intellectual Property Development Limited
- Current Assignee: GlaxoSmith Kline Intellectual Property Development Limited
- Current Assignee Address: GB Middlesex
- Agent W. Brett Stauffer
- Main IPC: A61K31/675
- IPC: A61K31/675 ; A61P35/02 ; A61K31/44 ; C07D213/85 ; C07F9/58
Abstract:
The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.
Public/Granted literature
- US20230101987A1 SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS Public/Granted day:2023-03-30
Information query
